These findings suggest that PTEN loss may represent a more clinically significant chromosomal alteration in PCa compared to TMPRSS2:ERG fusion emphasising its importance as a potential biomarker and therapeutic target. The gene discussed is TMPRSS2; the disease is posterior cortical atrophy.